Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Citizens JMP Life Sciences Conference 2024
22 slides from Mayne Pharma's conference presentation, May 13, 2024
Slide 1: Mayne Pharma presentation at Citizens JMP Life Sciences Conference
ASX Announcement MAYNE PHARMA PRESENTATION AT CITIZENS JMP LIFE SCIENCES CONFERENCE 13 May 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the Citizens JMP Life Sciences Conference i
Slide 2: Mayne Pharma Group Limited - Citizens JMP Healthcare Conference
For personal use only Mayne Pharma Group Limited CITIZENS JMP Healthcare Conference Shawn Patrick O’Brien CEO & Managing Director May 13, 2024 MYX.ASX
Slide 3: Disclaimer
Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential inves
Slide 4: Mayne Pharma: Improving patient access to life-enhancing medications
Mayne Pharma: Improving patient access to life-enhancing medications ● Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing For personal use only branded pharmaceuticals. Women’s Health Dermatology International Reproductive Health Proprietary Brands • Flagship p
Slide 5: FY2024 Goals
FY2024 Goals For personal use only Deliver positive Optimize cost base Return Company to Return Company to direct contribution1 with OPEX and NEXTSTELLIS® run positive operating positive underlying in all three other reductions of rate breakeven cash generation in EBITDA in FY24 segments >US$10m FY2
Slide 6: 1HFY24 Achieved out of FY24 Goals
1HFY24 Achieved 4 out of 5 FY24 Goals Deliver positive direct Return Company to Optimise cost base with Return Company to NEXTSTELLIS® run rate For personal use only contribution in all three positive underlying EBITDA OPEX and other reductions positive operating cash breakeven segments in FY24 of >
Slide 7: Group Continuing Operations Financial Overview
Group Continuing Operations Financial Overview: Improved operational performance1 Change vs A$ million2 1HFY23 2HFY23 1HFY24 2HFY23 For personal use only Reported Revenue $52.2 $131.4 $187.9 $56.5 Reported Gross Profit $15.1 $68.4 $105.8 $37.4 Reported Direct Contribution ($45.6) $3.8 $40.6 $36.8 Re
Slide 8: Addressing the Change Healthcare Security Breach
Addressing the Change Healthcare Security Breach For personal use only ● As reported by the industry, in February, there was a cyberattack on Change Healthcare, which operates the largest clearinghouse for medical claims in the U.S. ● This attack impacted the ability of providers to send claims to p
Slide 9: Women's Health
For personal use only Women’s Health
Slide 10: Leader in U.S. Women's Health
Leader in U.S. Women’s Health ● A leading position in strong and growing market with four novel women’s healthcare products For personal use only ● Licensing rights acquisition added a complementary portfolio of stable products with long patent lives to the Company’s flagship women’s health produc
Slide 11: Women's Health: continued growth
Women’s Health: continued growth Women’s Health For personal use only Women's Health in USD'000 1HFY23 2HFY23 1HFY24 Total Revenue 9,005 32,667 47,277 • Direct contribution A$18.1m in 1HFY24 vs Total Gross Profit 7,183 29,096 38,334 A($1.7m) in 2HFY23 Total Gross Profit % of Revenue 80% 89% 81% • NE
Slide 12: Women's Health: top line portfolio growth
Women’s Health: top line portfolio growth Sales in USD ‘000 Monthly NEXTSTELLIS® IQVIA reported UNITS in ‘000s (1) 50,000 For personal use only 45.0K 40.8K 1,841 40.0K 37.6K 5,040 36.4K 36.4K 33.6K 34.1K 40,000 35.0K 32.4K 30.5K 29.5K 10,776 30.0K 26.9K 25.3K 2,224 23.2K 30,000 25.0K 2,855 21.4K 20.
Slide 13: Dermatology
For personal use only Dermatology
Slide 14: Dermatology / Portfolio Products Division (PPD)
Dermatology / Portfolio Products Division (PPD) Building market leadership and scale For personal use only ● Six proprietary brands and 20 generic dermatologics ● Mayne Pharma portfolio can fill 1 in 3 US Dermatology Retail Rx’s1 ● Recent growth driving by acquisition of RHOFADE®, an FDA-approved to
Slide 15: Dermatology: delivering on new product launches and channel strategy
Dermatology: delivering on new product launches and channel strategy Dermatology For personal use only Derm in USD'000 1HFY23 2HFY23 1HFY24 Total Revenue 7,495 30,878 52,855 Total Gross Profit (3,036) 10,226 23,908 • Direct contribution A$18.1m in 1HFY24 vs Total Gross Profit % of Revenue -41% 33% 4
Slide 16: Dermatology Growth Products: TRx and Market Share
Dermatology Growth Products: TRx and Market Share For personal use only Market Share* by Month 100% 87% 88% 89% 90% 50% 34% 34% 35% 34% 18% 21% 1% 10% 6% 13% 14% 0% Rhofade Cream 1% Doryx MPC 60 GxAccutane - Mayne Soolantra AG December Market Share January Market Share February Market Share March Ma
Slide 17: Patient Ease of Access or Disintermediation Strategy
Patient Ease of Access or Disintermediation Strategy Mayne Pharma’s unique platform spans the entire value chain, allowing for the ability to create a comprehensive, frictionless, transparent, and cost-effective experience For personal use only ● Launched pilot program with GoodRx in 1HFY24 in Women
Slide 18: International
For personal use only International
Slide 19: International: improved financial profile
International: improved financial profile For personal use only International International in AUD'000 1HFY23 2HFY23 1HFY24 Reported Revenue 27,626 37,079 34,608 Reported Gross Profit 8,876 10,048 10,480 Total Gross Profit % of Revenue 32% 27% 30% • 2-year agreement signed for the supply Direct OPEX
Slide 20: Remainder of FY2024 Outlook
For personal use only Remainder of FY2024 Outlook
Slide 21: 2HFY24 Outlook and Key Focus
2HFY24 Outlook and Key Focus Expected to grow both revenue and earnings 2H24 vs. 1H24 For personal use only WOMEN’S HEALTH DERMATOLOGY Continued revenue growth with improving • Continued growth across all Women’s • Maintenance of margin profile via more cost leverage and Health brands, continued ope
Slide 22: Q&A
Q&A For personal use only Shawn Patrick O’Brien CEO Mayne Pharma Group Limited MYX.ASX You deserve tomorrow. 21
Mayne Pharma Group — Citizens JMP Life Sciences Conference 2024 on 6ix